Milnacipran - Isotope Labelled Standards
References
FAQ's
References
- Hascoet, Pierre; Cousse, Henri, Industrial process for producing Midalcipran, FR2581060B1, Apr 25, 1985, P. F. Medicament, France (https://www.lens.org/lens/search/patent/list?q=FR2581060A1)
- Puozzo, Christian; Filaquier, Christian; Zorza, Gregoire, Determination of milnacipran, a serotonin and noradrenaline reuptake inhibitor, in human plasma using liquid chromatography with spectrofluorimetric detection, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 806, Issue: 2, Pages: 221-228, 2004 DOI: (10.1016/j.jchromb.2004.03.063)
Frequently Asked Questions
What are the analytical methods to characterize Milnacipran impurities?
IR, LC-MS, 1H NMR, and 13C NMR are the analytical methods that characterize Milnacipran impurities.
How do process-related Milnacipran impurities form in the drug?
Contaminated raw materials, reagents, and unreacted catalysts during synthesis form process-related Milnacipran impurities.
Why is it necessary to remove Milnacipran impurities from the drug?
Milnacipran impurities can affect drug safety and quality and pose health risks, so it is necessary to remove them from the drug.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.